- Home
- PLBY vs VYNE Comparison
PLBY vs VYNE Comparison
Compare PLBY & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLBY
- VYNE
- Stock Information
- Founded
- PLBY 1953
- VYNE 2003
- Country
- PLBY United States
- VYNE United States
- Employees
- PLBY N/A
- VYNE N/A
- Industry
- PLBY Recreational Games/Products/Toys
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- PLBY Consumer Discretionary
- VYNE Health Care
- Exchange
- PLBY Nasdaq
- VYNE Nasdaq
- Market Cap
- PLBY 53.2M
- VYNE 38.2M
- IPO Year
- PLBY N/A
- VYNE 2018
- Fundamental
- Price
- PLBY $0.68
- VYNE $1.89
- Analyst Decision
- PLBY Buy
- VYNE Strong Buy
- Analyst Count
- PLBY 2
- VYNE 1
- Target Price
- PLBY $2.35
- VYNE $5.75
- AVG Volume (30 Days)
- PLBY 245.9K
- VYNE 41.7K
- Earning Date
- PLBY 11-07-2024
- VYNE 11-11-2024
- Dividend Yield
- PLBY N/A
- VYNE N/A
- EPS Growth
- PLBY N/A
- VYNE N/A
- EPS
- PLBY N/A
- VYNE N/A
- Revenue
- PLBY $125,850,000.00
- VYNE $486,000.00
- Revenue This Year
- PLBY N/A
- VYNE $32.31
- Revenue Next Year
- PLBY N/A
- VYNE N/A
- P/E Ratio
- PLBY N/A
- VYNE N/A
- Revenue Growth
- PLBY N/A
- VYNE 19.41
- 52 Week Low
- PLBY $0.43
- VYNE $1.57
- 52 Week High
- PLBY $1.55
- VYNE $4.48
- Technical
- Relative Strength Index (RSI)
- PLBY 54.98
- VYNE 50.56
- Support Level
- PLBY $0.72
- VYNE $1.79
- Resistance Level
- PLBY $0.77
- VYNE $2.10
- Average True Range (ATR)
- PLBY 0.05
- VYNE 0.11
- MACD
- PLBY 0.00
- VYNE 0.01
- Stochastic Oscillator
- PLBY 32.18
- VYNE 32.47
About PLBY PLBY Group Inc.
PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.